Current Environment: Production

Medical Services

Specialties

Programs & Services

Languages

  • English
  • Hebrew

Education

Medical School

Boston University School of Medicine

1982, Boston, MA

Internship

Babies Hospital

1983, New York, NY

Residency

Babies Hospital

1985, New York, NY

Fellowship

Boston Children's Hospital

1989, Boston, MA

Certifications

  • American Board of Pediatrics (General)
  • American Board of Pediatrics (Rheumatology)

Publications

  1. Rapid Improvement in Recalcitrant Cutaneous Juvenile Dermatomyositis With Anifrolumab Treatment. JAMA Dermatol. 2024 02 01; 160(2):237-238. View Abstract

  2. Implications of Inflammatory Processes on a Developing Central Nervous System in Childhood-Onset Systemic Lupus Erythematosus. Arthritis Rheumatol. 2024 Mar; 76(3):332-344. View Abstract

  3. Elevation of IL-17 Cytokines Distinguishes Kawasaki Disease From Other Pediatric Inflammatory Disorders. Arthritis Rheumatol. 2024 02; 76(2):285-292. View Abstract

  4. Type I interferon signature and cycling lymphocytes in macrophage activation syndrome. J Clin Invest. 2023 11 15; 133(22). View Abstract

  5. Incidence and Risk Factors for Eosinophilia and Lung Disease in Biologic-Exposed Children With Systemic Juvenile Idiopathic Arthritis. Arthritis Care Res (Hoboken). 2023 10; 75(10):2063-2072. View Abstract

  6. Disordered T cell-B cell interactions in autoantibody-positive inflammatory arthritis. Front Immunol. 2022; 13:1068399. View Abstract

  7. An Evidence-Based Guideline Improves Outcomes for Patients With Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome. J Rheumatol. 2022 Sep; 49(9):1042-1051. View Abstract

  8. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease. Arthritis Rheumatol. 2022 04; 74(4):586-596. View Abstract

  9. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease. Arthritis Care Res (Hoboken). 2022 04; 74(4):538-548. View Abstract

  10. Proteomics based markers of clinical pain severity in juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2022 Jan 15; 20(1):3. View Abstract

  11. Th1 polarization defines the synovial fluid T cell compartment in oligoarticular juvenile idiopathic arthritis. JCI Insight. 2021 09 22; 6(18). View Abstract

  12. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. Arthritis Rheumatol. 2021 08; 73(8):1384-1393. View Abstract

  13. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Rheumatol. 2021 08; 73(8):1349-1365. View Abstract

  14. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. Arthritis Care Res (Hoboken). 2021 08; 73(8):1061-1070. View Abstract

  15. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2021 08; 73(8):1366-1383. View Abstract

  16. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Care Res (Hoboken). 2021 08; 73(8):1071-1087. View Abstract

  17. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Care Res (Hoboken). 2021 08; 73(8):1088-1105. View Abstract

  18. A multidisciplinary assessment of pain in juvenile idiopathic arthritis. Semin Arthritis Rheum. 2021 08; 51(4):700-711. View Abstract

  19. Cyclophosphamide use in treatment of refractory Kawasaki disease with coronary artery aneurysms. Pediatr Rheumatol Online J. 2021 Mar 17; 19(1):31. View Abstract

  20. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clin Infect Dis. 2021 01 23; 72(1):1-8. View Abstract

  21. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clin Infect Dis. 2021 01 23; 72(1):e1-e48. View Abstract

  22. Multiple Emergency Department Visits for a Diagnosis of Kawasaki Disease: An Examination of Risk Factors and Outcomes. J Pediatr. 2021 05; 232:127-132.e3. View Abstract

  23. Clinical Practice Guidelines by the Infectious Diseases Society of America, American Academy of Neurology, and American College of Rheumatology: 2020 Guidelines for the Prevention, Diagnosis, and Treatment of Lyme Disease. Neurology. 2021 02 09; 96(6):262-273. View Abstract

  24. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis, and Treatment of Lyme Disease. Arthritis Care Res (Hoboken). 2021 01; 73(1):1-9. View Abstract

  25. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis, and Treatment of Lyme Disease. Arthritis Rheumatol. 2021 01; 73(1):12-20. View Abstract

  26. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children. J Clin Invest. 2020 11 02; 130(11):5942-5950. View Abstract

  27. Primary adjunctive corticosteroid therapy is associated with improved outcomes for patients with Kawasaki disease with coronary artery aneurysms at diagnosis. Arch Dis Child. 2021 03; 106(3):247-252. View Abstract

  28. Th17 reprogramming of T cells in systemic juvenile idiopathic arthritis. JCI Insight. 2020 03 26; 5(6). View Abstract

  29. Posterior-onset Rasmussen's encephalitis with ipsilateral cerebellar atrophy and uveitis resistant to rituximab. Epilepsy Behav Rep. 2020; 14:100360. View Abstract

  30. Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2020 02; 79(2):225-231. View Abstract

  31. Risk Model Development and Validation for Prediction of Coronary Artery Aneurysms in Kawasaki Disease in a North American Population. J Am Heart Assoc. 2019 06 04; 8(11):e011319. View Abstract

  32. Pediatric CNS-isolated hemophagocytic lymphohistiocytosis. Neurol Neuroimmunol Neuroinflamm. 2019 05; 6(3):e560. View Abstract

  33. Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome. Pediatr Rheumatol Online J. 2019 Feb 14; 17(1):7. View Abstract

  34. Disrupted N-linked glycosylation as a disease mechanism in deficiency of ADA2. J Allergy Clin Immunol. 2018 10; 142(4):1363-1365.e8. View Abstract

  35. Association Between Dose of Glucocorticoids and Coronary Artery Lesions in Kawasaki Disease. Arthritis Care Res (Hoboken). 2018 07; 70(7):1052-1057. View Abstract

  36. Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America. Pediatr Rheumatol Online J. 2017 Jun 13; 15(1):50. View Abstract

  37. Predicting Coronary Artery Aneurysms in Kawasaki Disease at a North American Center: An Assessment of Baseline z Scores. J Am Heart Assoc. 2017 May 31; 6(6). View Abstract

  38. National survey of pediatric hospitalizations due to Kawasaki disease and coronary artery aneurysms in the USA. Clin Rheumatol. 2017 Feb; 36(2):413-419. View Abstract

  39. Evidence-based decision support for pediatric rheumatology reduces diagnostic errors. Pediatr Rheumatol Online J. 2016 Dec 13; 14(1):67. View Abstract

  40. Clarifying the Role of Corticosteroids in Kawasaki Disease. JAMA Pediatr. 2016 12 01; 170(12):1140-1142. View Abstract

  41. Kawasaki Disease at 50 Years. JAMA Pediatr. 2016 11 01; 170(11):1093-1099. View Abstract

  42. Nationwide epidemiological survey of childhood IgA vasculitis associated hospitalization in the USA. Clin Rheumatol. 2016 Nov; 35(11):2749-2756. View Abstract

  43. Next-Generation Sequencing Reveals Restriction and Clonotypic Expansion of Treg Cells in Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2016 07; 68(7):1758-68. View Abstract

  44. Kawasaki disease. Rheum Dis Clin North Am. 2015; 41(1):63-73, viii. View Abstract

  45. Idiopathic pericarditis and pericardial effusion in children: contemporary epidemiology and management. J Am Heart Assoc. 2014 Nov 07; 3(6):e001483. View Abstract

  46. Pain hypersensitivity in juvenile idiopathic arthritis: a quantitative sensory testing study. Pediatr Rheumatol Online J. 2014; 12:39. View Abstract

  47. Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors. J Rheumatol. 2014 Jun; 41(6):1163-70. View Abstract

  48. A119: deep sequencing analysis of the T regulatory and T effector repertoire in juvenile idiopathic arthritis. Arthritis Rheumatol. 2014 Mar; 66 Suppl 11:S156. View Abstract

  49. Hypergammaglobulinemia in the pediatric population as a marker for underlying autoimmune disease: a retrospective cohort study. Pediatr Rheumatol Online J. 2013 Nov 01; 11(1):42. View Abstract

  50. Urine proteomics for discovery of improved diagnostic markers of Kawasaki disease. EMBO Mol Med. 2013 Feb; 5(2):210-20. View Abstract

  51. Pediatric chronic nonbacterial osteomyelitis. Pediatrics. 2012 Nov; 130(5):e1190-7. View Abstract

  52. Paediatric rheumatic disease: Classification warfare. Nat Rev Rheumatol. 2012 Oct; 8(10):570-2. View Abstract

  53. Multiple juvenile idiopathic arthritis subtypes demonstrate proinflammatory IgG glycosylation. Arthritis Rheum. 2012 Sep; 64(9):3025-33. View Abstract

  54. Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective randomized trial. Lupus. 2012 Nov; 21(13):1433-43. View Abstract

  55. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012 Jun; 64(6):2012-21. View Abstract

  56. Putting collagen back in the collagen vascular disorders. Rheumatology (Oxford). 2011 Dec; 50 Suppl 5:v60-2. View Abstract

  57. Primary lyme arthritis of the pediatric hip. J Pediatr Orthop. 2011 Oct-Nov; 31(7):787-90. View Abstract

  58. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr. 2011 Apr; 158(4):644-649.e1. View Abstract

  59. Musculoskeletal causes of pediatric chest pain. Pediatr Clin North Am. 2010 Dec; 57(6):1385-95. View Abstract

  60. Outcomes of children treated for Lyme arthritis: results of a large pediatric cohort. J Rheumatol. 2010 May; 37(5):1049-55. View Abstract

  61. Performance of 2004 American Heart Association recommendations for treatment of Kawasaki disease. Pediatrics. 2010 Feb; 125(2):e234-41. View Abstract

  62. Atypical and incomplete Kawasaki disease. Best Pract Res Clin Rheumatol. 2009 Oct; 23(5):689-97. View Abstract

  63. Editorial: Do no harm--first but not only. Curr Opin Rheumatol. 2009 Sep; 21(5):531-2. View Abstract

  64. Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics. 2009 Jul; 124(1):1-8. View Abstract

  65. Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis Rheum. 2009 Jun; 60(6):1825-1830. View Abstract

  66. MRI findings of juvenile psoriatic arthritis. Skeletal Radiol. 2008 Nov; 37(11):987-96. View Abstract

  67. Chronic minocycline-induced autoimmunity in children. J Pediatr. 2008 Sep; 153(3):314-9. View Abstract

  68. Comparison of Vancouver and International League of Associations for rheumatology classification criteria for juvenile psoriatic arthritis. Arthritis Rheum. 2008 Jan 15; 59(1):51-8. View Abstract

  69. Delayed diagnosis of Kawasaki disease: what are the risk factors? Pediatrics. 2007 Dec; 120(6):e1434-40. View Abstract

  70. Characteristics of children discharged from hospitals in the United States in 2000 with the diagnosis of acute rheumatic fever. Pediatrics. 2007 Sep; 120(3):503-8. View Abstract

  71. Vasculitis in children. Rheum Dis Clin North Am. 2007 Aug; 33(3):555-83. View Abstract

  72. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. J Pediatr. 2007 Apr; 150(4):376-82. View Abstract

  73. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med. 2007 Feb 15; 356(7):663-75. View Abstract

  74. Gene-expression patterns reveal underlying biological processes in Kawasaki disease. Genome Biol. 2007; 8(12):R261. View Abstract

  75. Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database. Arthritis Rheum. 2006 Dec; 54(12):3971-8. View Abstract

  76. Patients with juvenile psoriatic arthritis comprise two distinct populations. Arthritis Rheum. 2006 Nov; 54(11):3564-72. View Abstract

  77. Family-based association analysis implicates IL-4 in susceptibility to Kawasaki disease. Genes Immun. 2005 Aug; 6(5):438-44. View Abstract

  78. MRI features of Lyme arthritis in children. AJR Am J Roentgenol. 2005 Jun; 184(6):1904-9. View Abstract

  79. Coronary artery dilation among patients presenting with systemic-onset juvenile idiopathic arthritis. Pediatrics. 2005 Jul; 116(1):e89-93. View Abstract

  80. Vasculitis in children. Pediatr Clin North Am. 2005 Apr; 52(2):547-75, vii. View Abstract

  81. Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study. J Pediatr. 2004 Dec; 145(6):856-7. View Abstract

  82. Rituximab therapy for multisystem autoimmune diseases in pediatric patients. J Pediatr. 2003 Nov; 143(5):598-604. View Abstract

  83. A clinical practice guideline for treatment of septic arthritis in children: efficacy in improving process of care and effect on outcome of septic arthritis of the hip. J Bone Joint Surg Am. 2003 Jun; 85(6):994-9. View Abstract

  84. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr. 2003 Jun; 142(6):611-6. View Abstract

  85. Raynaud's phenomenon in children: a retrospective review of 123 patients. Pediatrics. 2003 Apr; 111(4 Pt 1):715-21. View Abstract

  86. Physical and psychosocial health in children who have had Kawasaki disease. Pediatrics. 2003 Mar; 111(3):579-83. View Abstract

  87. Update on the treatment of Kawasaki disease in childhood. Curr Rheumatol Rep. 2002 Dec; 4(6):474-82. View Abstract

  88. Fibroblastic rheumatism: case report and review of the literature. Pediatr Dermatol. 2002 Nov-Dec; 19(6):532-5. View Abstract

  89. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol. 2002 Oct; 47(4):505-11. View Abstract

  90. Vasculitis in childhood. Rheum Dis Clin North Am. 2002 Aug; 28(3):625-54. View Abstract

  91. Prolonged sensory and motor deficit following short-term lumbar epidural analgesia in a patient with mixed connective tissue disease. J Pain Symptom Manage. 2002 Feb; 23(2):89-92. View Abstract

  92. Vasculitis in childhood. Curr Opin Rheumatol. 2001 Sep; 13(5):422-7. View Abstract

  93. Treatment of TRAPS with etanercept: use in pediatrics. Clin Exp Rheumatol. 2001 Jul-Aug; 19(4):484-5. View Abstract

  94. Aortic root dilation in Kawasaki disease. Am J Cardiol. 2001 Apr 01; 87(7):919-22. View Abstract

  95. Psoriatic eruption in Kawasaki disease. J Pediatr. 2000 Oct; 137(4):578-80. View Abstract

  96. Ticlopidine plus aspirin for coronary thrombosis in Kawasaki disease. Pediatrics. 2000 May; 105(5):E64. View Abstract

  97. Report of the National Institutes of Health Workshop on Kawasaki Disease. J Rheumatol. 1999 Jan; 26(1):170-90. View Abstract

  98. Outcomes of children treated for Lyme disease. J Rheumatol. 1998 Nov; 25(11):2249-53. View Abstract

  99. Parvovirus B19-associated interstitial lung disease, hepatitis, and myositis. Pediatr Pulmonol. 1998 Nov; 26(5):365-9. View Abstract

  100. Coronary artery dimensions may be misclassified as normal in Kawasaki disease. J Pediatr. 1998 Aug; 133(2):254-8. View Abstract

  101. A predictive instrument for coronary artery aneurysms in Kawasaki disease. US Multicenter Kawasaki Disease Study Group. Am J Cardiol. 1998 May 01; 81(9):1116-20. View Abstract

  102. Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I/II study. Pediatric Rheumatology Collaborative Study Group. J Rheumatol. 1996 May; 23(5):919-24. View Abstract

  103. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr. 1996 Jan; 128(1):146-9. View Abstract

  104. Osteomyelitis and septic arthritis in children: appropriate use of imaging to guide treatment. AJR Am J Roentgenol. 1995 Aug; 165(2):399-403. View Abstract

  105. Acquired C1 inhibitor deficiency as a result of an autoantibody to the reactive center region of C1 inhibitor. J Immunol. 1994 May 01; 152(9):4680-5. View Abstract

  106. Kawasaki disease and its cardiac sequelae. Hosp Pract (Off Ed). 1993 Nov 15; 28(11):51-4, 57-60, 64-6. View Abstract

  107. Kawasaki disease and acute renal failure. Pediatr Nephrol. 1993 Oct; 7(5):593. View Abstract

  108. Gamma globulin re-treatment in Kawasaki disease. J Pediatr. 1993 Oct; 123(4):657-9. View Abstract

  109. Audiologic profiles of children with Kawasaki disease. Am J Otol. 1992 Nov; 13(6):512-5. View Abstract

  110. Decreased protein binding of salicylates in Kawasaki disease. J Pediatr. 1991 Mar; 118(3):456-9. View Abstract

  111. Sensorineural hearing loss associated with Kawasaki disease. J Pediatr. 1990 Sep; 117(3):371-7. View Abstract

  112. Kawasaki disease. Curr Opin Rheumatol. 1990 Feb; 2(1):81-6. View Abstract
BESbswy